Open AccessDetection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America
Author(s) -
Betsy Esperanza Castro,
Maritza Berrío,
Mónica L Vargas,
Lina P Carvajal,
Lina V Millan,
Rafael Ríos,
Angie K Hernandez,
Sandra Rincón,
Paola Cubides,
Erika Forero,
An Q Dinh,
Carlos Seas,
José M. Munita,
César A. Arias,
Jinnethe Reyes,
Lorena Díaz
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa221
Subject(s) - etest , vancomycin , rpob , microbiology and biotechnology , staphylococcus aureus , methicillin resistant staphylococcus aureus , population , teicoplanin , medicine , glycopeptide , biology , antibiotics , bacteria , genetics , 16s ribosomal rna , environmental health
Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.